Focus: Recordati is a mid-cap specialty pharma focused on small molecule manufacturing across oncology, endocrinology, rare diseases, cardiovascular, and hematology. The company operates at scale with 1,001-5,000 employees as a public entity.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Recordati to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Recordati
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Recordati's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anchor franchise generating 67% of company revenue with 11beta-hydroxylase inhibition mechanism and extended patent protection to 2035.
Second-largest revenue contributor in rare metabolic disorders; patent expiration in January 2028 creates near-term revenue headwind.
Niche rare disease therapy with cystine-depleting mechanism addressing unmet need in pediatric cystinosis management.
Biologic complement pathway inhibitor in emerging rare hematologic indication with no near-term LOE.
Somatostatin receptor agonist with patent expiration December 2026; lower current revenue but historical significance in neuroendocrine disorders.
7 discontinued, 5 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
+2 more products
Showing 5 of 10 publications